

Answer to the Reviewers

Reviewer # 1

1. The "Introduction" section were reduced as suggested by the reviewer. The first paragraph was reduced dramatically and all the epidemiological data were cut. Thus, the first two paragraphs were integrated in only one. Clinical trials and meta-analyses studies were excluded from the "Introduction".
2. The aim of the study was added at the end of "Introduction" section as suggested by the reviewer.
3. Clinical trials should be discussed before the prognostic factors discussion because they indicate the present treatment strategy and evidence. The randomized phase III trials have not offered strong evidence of therapy in gastric cancer patients. For this reason, prognostic factors are need to help clinicians in the clinical practice, but there is still no strong evidence regarding their use in phase III studies. We think that, what we know should be put first and what is new should come next.
4. Grammatical errors have been corrected.
5. Only older publications that are important for the discussion were left (randomized trials), Ref 14, 15 and 31 were cancelled from the paper. References were updated.

Reviewer # 2

Three figures and one table were added to make more interesting this issue as suggested by the reviewer. They are be presented in the order that they appear in the main text of the manuscript: section "ROLE OF ADJUVANT CHEMORADIATION IN THE RANDOMIZED TRIALS " - Table 1; section "POST-OPERATIVE CHEMORADIATION AFTER D2 LYMPH NODE RESECTION" - Figure 1, 2 and 3.